Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (341-350 of 394) with videos related to

Pageof 40
Sort By:
Nature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.
The British Journal of Dermatology|September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trialsEric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
The Journal of Clinical Investigation|January 16, 2019
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosusRichard Furie, Victoria P Werth, Joseph F Merola, et al.
JAMA Dermatology|June 26, 2020
Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusScott A Elman, Cara Joyce, Kara Braudis, et al.
Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
Rheumatology and Therapy|May 5, 2025
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Pageof 40

Showing results (341-350 of 394) with videos related to

Sort By:
Pageof 40
Nature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.
The British Journal of Dermatology|September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trialsEric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
The Journal of Clinical Investigation|January 16, 2019
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosusRichard Furie, Victoria P Werth, Joseph F Merola, et al.
JAMA Dermatology|June 26, 2020
Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusScott A Elman, Cara Joyce, Kara Braudis, et al.
Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
Rheumatology and Therapy|May 5, 2025
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Pageof 40